Pharming and Santarus announce initiation of Phase IIIb clinical study with RHUCIN in Acute Hereditary Angioedema
01-Mar-2011 -
Pharming Group NV and Santarus, Inc. announced that Pharming has begun an international, multicenter, randomized, placebo-controlled Phase IIIb clinical study evaluating the investigational drug RHUCIN® (recombinant human C1 inhibitor) for the treatment of acute attacks of angioedema in ...
clinical trials
hereditary angioedema
phase IIIb studies